Back أبراكسين Arabic Paclitaxel unido a proteínas Spanish Nab paklitakseel Estonian Paclitaxel lié à l'albumine French
 | This scientific article needs additional citations to secondary or tertiary sources. (November 2016) |
| Combination of | |
|---|---|
| Paclitaxel | Mitotic inhibitor |
| Albumin | Delivery vehicle |
| Clinical data | |
| Trade names | Abraxane, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619008 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.[2][3][4] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.[5] It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".[6]
This treatment was approved in the United States in 2005,[7] and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[8][9] In 2012, the FDA widened the approved uses to include treatment for NSCLC.[3][10] In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.[4]
- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
- ^ "Definition of "protein-bound paclitaxel"". National Cancer Institute Dictionary of Cancer Terms. February 2, 2011.
- ^ a b "FDA approves Celgene's Abraxane for lung cancer". Reuters. October 12, 2012.
- ^ a b Pollack A (7 September 2013). "F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer". New York Times. Retrieved 6 September 2013.
- ^ "Paclitaxel Albumin-stabilized Nanoparticle Formulation". National Cancer Institute Drug Information. 2006.
- ^ "Abraxane". Orpha Net. 6 September 2013. Retrieved 20 July 2015.
- ^ Knapp A (27 August 2020). "The Inside Story Of Biotech's Barnum And His Covid Cures". Forbes. Retrieved 27 August 2020.
- ^ "FDA Approval for Nanoparticle Paclitaxel". National Cancer Institute Drug Information. 2006.
- ^ "Abraxane EPAR". European Medicines Agency (EMA). 9 March 2020. Retrieved 9 March 2020.
- ^ "Paclitaxel (Abraxane)". U.S. Food and Drug Administration. 11 October 2012. Retrieved 10 December 2012.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search